Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIT vs SLIT for Grass Pollen Allergic Rhinitis
NCT06061848Phase 3Recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2030
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alutard phleum pratense and vitamin d in allergic rhinitis (AR) (3 arms). Primary endpoint: Combined Symptom and Medication Score. Started Feb 2023; status: recruiting.
02
Drugs
alutard phleum pratensevitamin d
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06061848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061848.